Drug intelligence / Profile preview

FUSE202

Development stage: Preclinical
Lead developer: Fusix Biotech
Modality: Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

FUSE202 is an investigational oncolytic virus therapy being developed by Fusix Biotech for the treatment of solid tumors. Built on the company's proprietary InFUSE platform, FUSE202 is an engineered viral vector designed to selectively replicate within and lyse cancer cells while simultaneously delivering a genetic payload. Specifically, FUSE202 encodes an undisclosed immune-stimulatory gene (referred to as 'Gene B') intended to modulate the tumor microenvironment and enhance systemic antitumor immune responses. The program is currently in the IND-enabling stage of development.

Targets

ISG15 (Interferon-stimulated gene 15)

Beyond the preview

Go deeper on FUSE202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FUSE202.

Explore the full profile